EUCTR2014-002996-27-GB进行中（未招募）1 期
Optimising effectiveness and minimising toxicity of intravenous salbutamol in children with acute asthma - PKPD of intravenous salbutamol in paediatric acute severe asthma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients aged 1-15 years (inclusive) with acute severe asthma as defined by the BTS guidelines are eligible
- •2. About to receive / receiving IVS
- •3. ED cohort: Patients being admitted for acute asthma treatment in the Royal London Hospital or St Mary’s Hospital EDs while the research nurse is in attendance
- •4. CATS cohort: Patients being retrieved by the CATS team to Great Ormond Street Hospital or St Mary’s Hospital PICU over the study period.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patients being admitted to hospital for a primary reason other than asthma management will be excluded from the study.
研究者
相似试验
进行中（未招募）
1 期
Improvement of outcome and reduction of toxicity in elderly patients withCD20+ aggressive B-cell lymphoma by an optimised schedule of themonoclonal antibody rituximab, substitution of conventional by anothervincristine and FDG-PET based reduction of therapy in combination withvitamin D substitutioDiffuse large B-cell lymphomaMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-019587-36-DEniversität des Saarlandes1,152
进行中（未招募）
不适用
Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie - ERBIMOXEUCTR2006-002744-28-DEiOMEDICO
招募中
2 期
Reduced Toxicity and Reduced Intensity conditioning chemotherapy using Fludarabine and Treosulfan in allogenic bone marrow transplantatioCTRI/2020/09/027731Tata Medical Center
招募中
不适用
Tolerated dose of Lomustine used in combination with Etoposide and Cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patientsThe participants are patients with lymphoma (Hodgkin's disease and NonHodgkins lymphoma) who are chemosensitive and have indication for hematopoietic stem cell transplantation (as refractoriness) - thus, they will be submitted to this new protocol (LEC-Lomustine, Etoposide and Cyclophosphamide) with evaluation of the maximum tolerated dose of Lomustine.Descriptors: Hodgkins LymphomaNonhodgkins LymphomaM9590/3RBR-10bj7s98niversidade Federal de Juiz de Fora
撤回
不适用
ight work SEH: minimize harmful health effects among caregivers on emergency care caused by night shifts.NL-OMON48023Jeroen Bosch Ziekenhuis73